PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.475 |
| Open | 0.482 |
| Bid | 0.000 x 1300 |
| Ask | 0.000 x 1800 |
| Day's Range | 0.450 - 0.483 |
| 52 Week Range | 0.380 - 0.920 |
| Volume | 365,418 |
| Avg. Volume | 607,573 |
| Market Cap | 69.146M |
| Beta | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.261 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.30 |
- GlobeNewswire•5 days ago
Protalix BioTherapeutics Appoints David Granot to its Board of Directors
Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company’s Board of Directors has appointed Mr. David Granot to serve on the Company’s Board of Directors, effective on August 9, 2018. In addition to Mr. Granot’s appointment as an independent director, he was also appointed to serve on the Company’s Audit Committee.
- Zacks•9 days ago
Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•9 days ago
Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...
- Associated Press•9 days ago
Protalix: 2Q Earnings Snapshot
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...
- GlobeNewswire•9 days ago
Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update
CARMIEL, Israel, Aug. 09, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
- ACCESSWIRE•9 days ago
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Protalix Biotherapeutics, Inc. (NYSE: PLX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...
- ACCESSWIRE•18 days ago
Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).
- GlobeNewswire•18 days ago
Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018
CARMIEL, Israel, July 31, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
Market Realist•24 days agoWhy Protalix Expanded Partnership with Chiesi
On July 24, Protalix BioTherapeutics (PLX) expanded its partnership with Chiesi Farmaceutici. The expansion of the agreement allows Chiesi Farmaceutici exclusive US license for the development and commercialization of PRX-102 (pegunigalsidase alfa), which is Protalix’s modified version of the recombinant alpha-galactosidase-A protein. In October 2017, Protalix and Cheisi entered an exclusive partnership for the development and commercialization of PRX-102 outside the US for the treatment of individuals with Fabry disease.
- Benzinga•25 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...
- GlobeNewswire•25 days ago
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the expansion of its partnership with Chiesi Farmaceutici S.p.A., or Chiesi. Protalix and Chiesi entered into an exclusive U.S. license and supply agreement which grants to Chiesi the United States rights for the development and commercialization of PRX-102 (pegunigalsidase alfa), the Company’s chemically modified version of the recombinant protein alpha-Galactosidase-A protein, for the treatment of Fabry disease.
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on PBYI sign up now at www.wallstequities.com/registration. The Company's shares have gained 8.95% in the last month, 10.72% over the last three months, and 18.26% over the past year.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing. Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients. 89% of the ...
- ACCESSWIRE•3 months ago
Wired News - Protalix BioTherapeutics Presents Data About Fabry Disease Patients Screened in Phase-III BALANCE Study
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PLX as the Company's latest news hit the wire. On May 25, 2018, the Biopharmaceutical Company, which is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system ProCellEx, declared that it showcased data from the Phase-III BALANCE Study in a poster presentation at the 55th ERA-EDTA Congress (European Renal Association - European Dialysis and Transplant Association). Active-Investors.com is currently working on the research report for G1 Therapeutics, Inc. (NASDAQ: GTHX), which also belongs to the Healthcare sector as the Company Protalix BioTherapeutics.
- GlobeNewswire•3 months ago
Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that a poster presentation on the characteristics of Fabry disease patients screened in the phase III BALANCE clinical trial of pegunigalsidase alfa, a PEGylated alfa galactosidase alfa enzyme, or PRX-102, for the treatment of Fabry disease was presented at the 55th ERA-EDTA Congress (European Renal Association – European Dialysis and Transplant Association).
- GlobeNewswire•3 months ago
Protalix Announces Exchange and Discharge of Remaining 2018 Notes
Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (PLX.TA) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash. Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Notes to effectively discharge the remaining outstanding Notes. Additional details regarding the exchange can be found in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of PLX earnings conference call or presentation 9-May-18 12:30pm GMT
Q1 2018 Protalix Biotherapeutics Inc Earnings Call
- Associated Press•3 months ago
Protalix: 1Q Earnings Snapshot
The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...
- ACCESSWIRE•5 months ago
Protalix BioTherapeutics, OPRX-106 Phase II Results, Analysts Review and Target, Catalysts
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
